JP5290276B2 - システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体 - Google Patents

システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体 Download PDF

Info

Publication number
JP5290276B2
JP5290276B2 JP2010507620A JP2010507620A JP5290276B2 JP 5290276 B2 JP5290276 B2 JP 5290276B2 JP 2010507620 A JP2010507620 A JP 2010507620A JP 2010507620 A JP2010507620 A JP 2010507620A JP 5290276 B2 JP5290276 B2 JP 5290276B2
Authority
JP
Japan
Prior art keywords
antibody
muc16
cysteine
drug
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010507620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526821A (ja
JP2010526821A5 (enExample
Inventor
ヤガス アール． ユナトゥラ，
ウィリアム マレット，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2010526821A publication Critical patent/JP2010526821A/ja
Publication of JP2010526821A5 publication Critical patent/JP2010526821A5/ja
Application granted granted Critical
Publication of JP5290276B2 publication Critical patent/JP5290276B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010507620A 2007-05-08 2008-05-07 システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体 Expired - Fee Related JP5290276B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91665707P 2007-05-08 2007-05-08
US60/916,657 2007-05-08
PCT/US2008/062903 WO2008141044A2 (en) 2007-05-08 2008-05-07 Cysteine engineered anti-muc16 antibodies and antibody drug conjugates

Publications (3)

Publication Number Publication Date
JP2010526821A JP2010526821A (ja) 2010-08-05
JP2010526821A5 JP2010526821A5 (enExample) 2012-06-07
JP5290276B2 true JP5290276B2 (ja) 2013-09-18

Family

ID=39789637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010507620A Expired - Fee Related JP5290276B2 (ja) 2007-05-08 2008-05-07 システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体

Country Status (11)

Country Link
US (2) US7723485B2 (enExample)
EP (1) EP2144628B1 (enExample)
JP (1) JP5290276B2 (enExample)
CN (1) CN101687037B (enExample)
AR (1) AR066476A1 (enExample)
AU (1) AU2008251608B2 (enExample)
CA (1) CA2683568A1 (enExample)
CL (1) CL2008001334A1 (enExample)
PE (1) PE20090245A1 (enExample)
TW (1) TW200902554A (enExample)
WO (1) WO2008141044A2 (enExample)

Families Citing this family (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
USRE47223E1 (en) * 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
BRPI0818780A2 (pt) * 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
CA2745798A1 (en) * 2008-12-05 2010-06-10 The Government Of The U.S.A., As Represented By The Secretary, Departmen T Of Health & Human Services Blocking mesothelin peptide fragments
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
CN102666583B (zh) 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
EP2554669B1 (en) 2010-03-26 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Novel antibody having modification site introduced therein, and antibody fragment
CA2793753C (en) * 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
CA3220104A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
AU2011349443B2 (en) * 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびそのコンジュゲート
IN2014CN03887A (enExample) * 2011-10-27 2015-10-16 Genmab As
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
AU2013209512B2 (en) 2012-01-20 2017-08-03 I2 Pharmaceuticals, Inc. Surrobody cojugates
RU2582259C2 (ru) * 2012-02-24 2016-04-20 Алтеоген Инк. Модифицированные антитела, с которыми связан мотив, включающий остаток цистеина, конъюгаты этих модифицированных антител с лекарственными веществами и способ их получения
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
EP2906249B1 (en) 2012-10-12 2018-06-27 MedImmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
PT2906248T (pt) 2012-10-12 2019-03-04 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN103933575B (zh) 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
EA201591465A1 (ru) * 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
HK1219423A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US9580511B2 (en) 2013-03-11 2017-02-28 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
EP3964237B1 (en) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
MX369758B (es) 2013-05-31 2019-11-20 Genentech Inc Anticuerpos anti-acido teicoico de pared y conjugados.
PE20160715A1 (es) 2013-05-31 2016-08-01 Genentech Inc Anticuerpos frente a acidos teicoicos de pared y conjugados
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
CN110251683A (zh) * 2013-06-24 2019-09-20 Abl生物公司 具有改进的稳定性的抗体-药物缀合物及其用途
WO2015002486A1 (ko) 2013-07-03 2015-01-08 서울대학교산학협력단 시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합
JP2016523961A (ja) * 2013-07-09 2016-08-12 ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ ネブラスカＢｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｅｂｒａｓｋａ 癌を治療するための糖タンパク質の標的化方法
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
PT3480215T (pt) * 2013-11-19 2021-07-05 Remegen Ltd Anticorpo anti-her2 e seu conjugado
KR20160097336A (ko) 2013-12-12 2016-08-17 스템센트알엑스 인코포레이티드 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
CN104672330A (zh) * 2014-03-11 2015-06-03 南京任诺药业有限公司 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-N267C
CN104788566A (zh) * 2014-03-11 2015-07-22 南京任诺药业有限公司 用于构建放射性同位素偶联标记的ADC药物的改造抗体IgG1-CH-V280C
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
MA39909B1 (fr) 2014-04-25 2019-05-31 Pf Medicament Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
CN106459204B (zh) 2014-04-25 2021-02-02 皮埃尔法布雷医药公司 Igf-1r抗体及其作为定位载体用于治疗癌症的用途
MX378281B (es) 2014-04-25 2025-03-10 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
SG10202102467RA (en) 2014-07-24 2021-04-29 Genentech Inc Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CA2957148A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
EP3549583A1 (en) * 2014-10-10 2019-10-09 Pfizer Inc Synergistic auristatin combinations
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
MX2017007231A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
KR20170086536A (ko) * 2014-12-03 2017-07-26 제넨테크, 인크. 항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
JP2018502839A (ja) * 2014-12-09 2018-02-01 アッヴィ・インコーポレイテッド Ｂｃｌ−ｘＬ阻害性化合物およびこれを含む抗体薬物コンジュゲート
RU2017123942A (ru) * 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
AU2015366284B2 (en) * 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
KR102672113B1 (ko) 2015-02-16 2024-06-03 론자 리미티드 Cl 및/또는 ch1 돌연변이된 약물 접합용 항체
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
CA2978340C (en) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
JP6957035B2 (ja) 2015-04-10 2021-11-02 トーマス・ジェファーソン・ユニバーシティ 対象への移植用の免疫原性拡散チャンバおよびその調製方法
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
US10017577B2 (en) * 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
JP6852065B2 (ja) 2015-10-20 2021-03-31 ジェネンテック， インコーポレイテッド カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
MX390128B (es) 2015-10-26 2025-03-20 Pf Medicament Composición para el tratamiento de cáncer con expresión del igf-1r.
US9669106B2 (en) 2015-10-26 2017-06-06 Pierre Fabre Medicament Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
EP3394096A1 (en) 2015-12-21 2018-10-31 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
IL290457B2 (en) * 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10899836B2 (en) * 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
BR112018014355A2 (pt) 2016-03-04 2018-12-18 Genentech, Inc. processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
EP3442979A4 (en) * 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
JP2019524706A (ja) * 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
AU2017312785B2 (en) * 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
CN118846112A (zh) * 2016-10-08 2024-10-29 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物及其制备方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
MX2019009372A (es) * 2017-02-08 2019-12-11 Pfizer Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas.
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US11666657B2 (en) 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
AU2018288029B2 (en) * 2017-06-19 2021-12-23 Systimmune, Inc. Antibody-drug conjugate having acidic self-stabilization junction
CN108743968B (zh) * 2017-06-20 2022-04-19 成都百利多特生物药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物(tdc)定点偶联位点筛选
MA68842B1 (fr) * 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
CN107583058B (zh) * 2017-09-20 2020-09-18 厉保秋 一种t-2毒素-抗体缀合物及其用途
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
CA3081925A1 (en) 2017-11-18 2019-05-23 Nzola DE MAGALHAES Product and process for employing gc7 (n1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy
CN115639361B (zh) * 2018-02-09 2025-07-18 北京豪迈生物工程股份有限公司 表面结合有抗体的颗粒
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN108727499B (zh) * 2018-04-24 2021-12-31 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108727498B (zh) * 2018-04-24 2021-11-26 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108714220B (zh) * 2018-04-24 2021-11-19 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN108743966B (zh) * 2018-04-24 2021-10-19 四川百利药业有限责任公司 半胱氨酸改造的抗体-毒素偶联物
CN112533957B (zh) 2018-06-04 2026-01-16 普瑞赛格恩公司 Muc16特异性嵌合抗原受体及其用途
CN111655295B (zh) 2018-08-29 2024-05-28 荣昌生物制药(烟台)股份有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202547837A (zh) 2018-09-11 2025-12-16 瑞士商赫孚孟拉羅股份公司 噻吩并－三唑并－二氮呯醋酸酯
WO2020079239A1 (en) 2018-10-19 2020-04-23 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20210081350A (ko) 2018-10-19 2021-07-01 메드임뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
JP7728701B2 (ja) 2018-12-17 2025-08-25 レビトープ リミテッド 双子型免疫細胞エンゲージャー
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
JP7575401B2 (ja) 2019-04-03 2024-10-29 ジェンザイム・コーポレーション 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド
CN111825742B (zh) * 2019-04-18 2024-01-30 陈铭 Ctpa作为特种偶合剂用于氨基酸离子液体的多肽固相合成
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP2022537158A (ja) 2019-06-13 2022-08-24 ボルト バイオセラピューティクス、インコーポレーテッド アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
AU2019452577B2 (en) 2019-06-29 2023-08-24 Hangzhou Dac Biotech Co., Ltd. Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor
US20220313835A1 (en) 2019-09-03 2022-10-06 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
EP4038053A1 (en) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021080608A1 (en) 2019-10-25 2021-04-29 Medimmune, Llc Branched moiety for use in conjugates
EP4048315B1 (en) 2019-10-25 2025-03-12 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
CN110922476A (zh) * 2019-12-16 2020-03-27 蓝怡科技集团股份有限公司 一种生物素偶联抗体及其制备方法和应用
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
US20230097908A1 (en) 2020-01-22 2023-03-30 Medimmune Limited Compounds and conjugates thereof
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
MX2023001679A (es) 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
KR20230060509A (ko) 2020-09-04 2023-05-04 노바록 바이오테라퓨틱스 리미티드 넥틴-4 항체 및 이의 용도
CN116829592A (zh) 2020-09-11 2023-09-29 免疫医疗有限公司 治疗性b7-h4结合分子
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
WO2022125891A2 (en) 2020-12-11 2022-06-16 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
JP2023552790A (ja) 2020-12-11 2023-12-19 ボルト バイオセラピューティクス、インコーポレーテッド 抗ｐｄ－ｌ１イムノコンジュゲート、及びそれらの使用
JP2023552791A (ja) 2020-12-11 2023-12-19 ボルト バイオセラピューティクス、インコーポレーテッド 抗ｈｅｒ２免疫複合体、及びその使用
CA3200056A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-her2 immunoconjugates, and uses thereof
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4308160A4 (en) * 2021-03-18 2025-07-02 Memorial Sloan Kettering Cancer Center METHODS OF TREATING GYNECOLOGICAL CANCER USING COMBINATION THERAPY WITH MULTISPECIFIC ANTI-MUC16 X CD3 ANTIBODIES AND VEGF INHIBITORS
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
CN117940168A (zh) 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
CN117769439A (zh) 2021-03-26 2024-03-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2022258829A1 (en) * 2021-04-16 2023-10-26 Novartis Ag Antibody drug conjugates and methods for making thereof
US20250000995A1 (en) 2021-10-29 2025-01-02 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
KR20240099430A (ko) 2021-11-10 2024-06-28 아스트라제네카 아베 항체 분자 및 접합체
WO2023088963A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-il-13ralpha2 conjugates
WO2023088966A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-psma conjugates
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
EP4230222A1 (en) 2022-02-17 2023-08-23 Oxsonics Limited Combination therapy with an anti-axl antibody-pbd conjugate and nanocups
CA3245067A1 (en) 2022-02-28 2023-08-31 Adc Therapeutics Sa DOSAGE REGIMEN
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
EP4490517A1 (en) 2022-03-11 2025-01-15 Astrazeneca AB A scoring method for an anti-fr alpha antibody-drug conjugate therapy
JP2025525410A (ja) 2022-06-27 2025-08-05 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ
CN119997982A (zh) 2022-09-09 2025-05-13 迈里克斯制药有限公司 包含nmt抑制剂的抗体药物偶联物及其用途
AU2023374571A1 (en) 2022-11-01 2025-04-03 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof
WO2024129756A1 (en) * 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
AU2023393382A1 (en) 2022-12-14 2025-06-19 Pheon Therapeutics Ltd Cytotoxic compounds
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
CN120417934A (zh) 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
EP4410314A1 (en) 2023-02-02 2024-08-07 ADC Therapeutics SA Combination therapy comprising anti-cd22 antibody-drug conjugate and irak1 inhibitor
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment
EP4701665A1 (en) 2023-04-28 2026-03-04 MedImmune Limited B7-h4 therapeutic binding molecules for the treatment of cancer
WO2025083061A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-napi2b conjugates
WO2025083067A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-claudin-6 conjugates
WO2025083064A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-asct2 conjugates
EP4548936A1 (en) 2023-10-30 2025-05-07 BioNTech SE Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
AU2024383376A1 (en) 2023-11-24 2026-05-28 Heidelberg Pharma Research Gmbh Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
US20250186604A1 (en) 2023-12-06 2025-06-12 Adc Therapeutics Sa Anti-psma antibody conjugates
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
EP4596569A1 (en) * 2024-02-05 2025-08-06 Syndivia Site specific antibody drug conjugates and their process of preparation
GB202403391D0 (en) 2024-03-08 2024-04-24 Myricx Pharma Ltd Novel compounds and their use in therapy
GB202405758D0 (en) 2024-04-24 2024-06-05 King S College London Compounds
GB202407700D0 (en) 2024-05-30 2024-07-17 Francis Crick Institute Ltd F-actin binding agents
TW202617186A (zh) 2024-06-28 2026-05-01 美商飛爾富來生物公司 Ｂｃｌ－ｘｌ降解劑抗體結合物及其用途
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
US20260078179A1 (en) 2024-07-18 2026-03-19 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof
WO2026050213A1 (en) 2024-08-27 2026-03-05 Usbolt Biotherapeutics, Inc. Tlr agonist immunoconjugates and uses thereof
WO2026055185A1 (en) 2024-09-04 2026-03-12 Bolt Biotherapeutics, Inc. Sting agonist immunoconjugates and uses thereof
WO2026057740A1 (en) 2024-09-12 2026-03-19 Astrazeneca Ab Treatment of cancer with therapeutic binding molecules
WO2026078620A1 (en) 2024-10-11 2026-04-16 Medimmune Llc Cd22 antibody and drug conjugates and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030078399A1 (en) 2001-05-11 2003-04-24 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
WO2003049704A2 (en) 2001-12-11 2003-06-19 University Of Massachusetts Antibodies to treat cancer
WO2004000547A1 (en) 2002-06-21 2003-12-31 Boler Lewyn B Jr Device and system for coating a surface
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
AU2003294355A1 (en) 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
ES2377979T3 (es) * 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JP2008519863A (ja) * 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
JP4987698B2 (ja) 2005-03-31 2012-07-25 中外製薬株式会社 癌関連抗原アナログペプチド、およびその利用
US7989595B2 (en) * 2005-06-20 2011-08-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos

Also Published As

Publication number Publication date
AR066476A1 (es) 2009-08-19
TW200902554A (en) 2009-01-16
US20080311134A1 (en) 2008-12-18
AU2008251608A1 (en) 2008-11-20
CN101687037B (zh) 2013-07-10
USRE47194E1 (en) 2019-01-08
PE20090245A1 (es) 2009-03-17
JP2010526821A (ja) 2010-08-05
US7723485B2 (en) 2010-05-25
CN101687037A (zh) 2010-03-31
CA2683568A1 (en) 2008-11-20
WO2008141044A3 (en) 2008-12-31
WO2008141044A2 (en) 2008-11-20
EP2144628B1 (en) 2012-10-17
EP2144628A2 (en) 2010-01-20
CL2008001334A1 (es) 2008-09-22
AU2008251608B2 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
CN101687037B (zh) 半胱氨酸改造的抗muc16抗体和抗体药物偶联物
CA2698541C (en) Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
KR101270829B1 (ko) 시스테인 유전자조작 항체 및 접합체
US20170362318A1 (en) Compositions and methods for the treatment of tumor hematopoietic origin
KR101884028B1 (ko) Ｓｌｃ３４ａ２ (ｔａｔ２１１ = 서열 ２)를 발현하는 종양의 치료 및 진단을 위한 항체
HK1143379B (en) Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130605

R150 Certificate of patent or registration of utility model

Ref document number: 5290276

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees